ArticleThe oncologist2025
In vitro drug sensitivity and clinical efficacy of the HAG regimen in pediatric AML.
Article in The oncologist, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundStandard induction chemotherapy for acute myeloid leukemia (AML) using cytarabine combined with anthracyclines (epirubicin/IA or daunorubicin/DA) is effective but associated with severe adverse effects. The HAG regimen (low-dose homoharringtonine, cytarabine, G-CSF), known for lower toxicity, shows promise in adult AML, but its application in pediatric AML remains underexplored.
methodsThis study investigated the feasibility and efficacy of the HAG regimen in pediatric AML. Twenty-four newly diagnosed pediatric AML patients (excluding M3 subtype) were enrolled between August 2021 and November 2022. Patients received the HAG regimen as induction therapy. Drug sensitivity testing was performed to evaluate in vitro efficacy.
resultsAfter the first induction cycle with HAG, the overall complete remission (CR) rate was 75% (18/24). Patients classified as ELN favorable and intermediate-risk achieved a 100% CR rate. The 1-year overall survival (OS) rate was 83.3% ± 7.6%, and the 3-year OS rate was 75.0% ± 8.8%. The 1-year event-free survival (EFS) rate was 75.0% ± 8.8%, and the 3-year EFS rate was 66.1% ± 9.8%.
conclusionThe HAG regimen demonstrates high efficacy and holds great promise for pediatric AML. It achieves survival outcomes comparable to more intensive regimens while offering the significant advantage of reduced toxicity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.